<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655706</url>
  </required_header>
  <id_info>
    <org_study_id>09-0117-A</org_study_id>
    <nct_id>NCT01655706</nct_id>
  </id_info>
  <brief_title>Canadian Biomarker Integration Network for Depression Study</brief_title>
  <acronym>CAN-BIND</acronym>
  <official_title>Integrated Biological Markers for the Prediction of Treatment Response in Depression: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot to assess feasibility of the protocol in patients and controls across
      six participating sites. The goal is to identify biological markers (biomarkers)that can be
      measured at baseline or early in treatment to predict treatment outcome in individual
      patients with Major Depressive Disorder (MDD). Biomarkers of interest will be clinical
      (using interview and self-report measures), molecular (from blood samples) and
      neurobiological (using neuroimaging and EEG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to collect clinical and biomarker data which will be used to build models to
      predict treatment response. This is not a study to evaluate efficacy of medications, as
      medications in this study have been approved by Health Canada and are widely used for the
      treatment of MDD.

      This is an open label study involving MDD patients and healthy controls.Patients with a
      diagnosis of MDD and a current major depressive episode (MDE) will receive open-label
      standard of care treatment with escitalopram (10-20mg). Healthy controls will not receive
      medication; however, they will go through clinical assessments, blood collection and
      neuroimaging procedures.

      At week 8, patients will be assessed for medication response (response is defined as ≥ 50%
      reduction in MADRS scores from baseline). Responders will continue medication at their
      effective dose until study endpoint while non-responders will receive open label add-on
      treatment with aripiprazole (2-10mg).

      There are approximately 7 clinic visits over a 16 week period during which patients and
      healthy controls will undergo clinician administered scales and self reports, provide blood
      and urine samples (which will undergo proteomic and genomic analyses) as well as
      neuroimaging (fMRI and EEG).

      At the end of the study, mathematical modeling methods will be used to integrate the data
      from the various modalities to see which features best predict treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in MADRS (Montgomery-Asberg Depression Rating Scale) scores from baseline</measure>
    <time_frame>Week 8, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical response (≥ 50% reduction in MADRS scores from baseline)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>escitalopram (10-20mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole (2-10mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.</description>
    <arm_group_label>escitalopram (10-20mg)</arm_group_label>
    <arm_group_label>aripiprazole (2-10mg)</arm_group_label>
    <other_name>Cipralex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.</description>
    <arm_group_label>aripiprazole (2-10mg)</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Depressed patients:

        Inclusion Criteria:

          -  Outpatients who are 18-55 years of age

          -  Meet DSM-IV-TR criteria for Major Depressive Episode in Major Depressive Disorder by
             the MINI

          -  Episode duration ≥ 3 months

          -  Free of psychotropic medications for at least 5 half-lives (i.e. 1 week for
             antidepressants, 5 weeks for fluoxetine) before baseline Visit 1

          -  MADRS ≥ 24

          -  Fluency in English, sufficient to complete the interviews and self-report
             questionnaires

        Exclusion Criteria:

          -  Any Axis I diagnosis other than MDD that is considered the primary diagnosis

          -  Bipolar I or Bipolar II diagnosis

          -  Presence of a significant Axis II diagnosis (borderline, antisocial)

          -  High suicidal risk, defined by clinician judgment

          -  Substance dependence/abuse in the past 6 months

          -  Presence of significant neurological disorders, head trauma or other unstable medical
             conditions

          -  Pregnant or breastfeeding

          -  Failure of 3 or more adequate pharmacologic interventions (as determined by the
             Antidepressant Treatment History Form)

          -  Started psychological treatment within the past 3 months with the intent of
             continuing treatment

          -  Patients who have previously failed escitalopram or showed intolerance to
             escitalopram and patients at risk for hypomanic switch (i.e. with a history of
             antidepressant hypomania)

        Inclusion criteria for Healthy Controls:

          -  18 to 55 years of age

          -  No history of Axis I or Axis II disorders, as determined by the MINI.

          -  Fluency in English, sufficient to complete the interviews and self-report
             questionnaires.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Kennedy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sidney Kennedy, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3888</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Rotzinger, PhD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6040</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Jaworska</last_name>
      <phone>403-210-7321</phone>
      <email>jaworskn@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Glenda MacQueen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Woo</last_name>
      <phone>604-822-7627</phone>
      <email>cindy.woo@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Raymond Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8P 3B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Woodford</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>32048</phone_ext>
      <email>twoodfor@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Benicio Frey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Walker</last_name>
      <phone>613-548-5567</phone>
      <phone_ext>6123</phone_ext>
      <email>walkerk1@providencecare.ca</email>
    </contact>
    <investigator>
      <last_name>Roumen Milev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Woldeyohannes</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>5133</phone_ext>
      <email>hannah.woldeyohannes@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Roger McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Ramirez</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>39273</phone_ext>
      <email>jonathan.ramirez@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Arun Ravindran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Placenza</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>8839</phone_ext>
      <email>franca.placenza@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Sidney Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.albertahealthservices.ca/7297.asp</url>
    <description>A news article from the Calgary site promoting the CAN-BIND project.</description>
  </link>
  <link>
    <url>http://www.canbind.ca</url>
    <description>CAN-BIND study website</description>
  </link>
  <reference>
    <citation>Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-89.</citation>
    <PMID>22681173</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Sidney Kennedy</investigator_full_name>
    <investigator_title>Psychiatrist-in-Chief</investigator_title>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>biomarkers</keyword>
  <keyword>escitalopram</keyword>
  <keyword>aripiprazole</keyword>
  <keyword>MDD</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>proteomic</keyword>
  <keyword>genomics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
